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Abstract
Therapies targeting the type I insulin-like growth factor receptor (IGF-1R) have not been
developed with predictive biomarkers to identify tumors with receptor activation. We have
previously shown that the insulin receptor substrate (IRS) adaptor proteins are necessary
for linking IGF1R to downstream signaling pathways and the malignant phenotype in breast
cancer cells. The purpose of this study was to identify gene expression profiles downstream
of IGF1R and its two adaptor proteins. IRS-null breast cancer cells (T47D-YA) were engi-
neered to express IRS-1 or IRS-2 alone and their ability to mediate IGF ligand-induced pro-
liferation, motility, and gene expression determined. Global gene expression signatures
reflecting IRS adaptor specific and primary vs. secondary ligand response were derived
(Early IRS-1, Late IRS-1, Early IRS-2 and Late IRS-2) and functional pathway analysis
examined. IRS isoforms mediated distinct gene expression profiles, functional pathways,
and breast cancer subtype association. For example, IRS-1/2-induced TGFb2 expression
and blockade of TGFb2 abrogated IGF-induced cell migration. In addition, the prognostic
value of IRS proteins was significant in the luminal B breast tumor subtype. Univariate and
multivariate analyses confirmed that IRS adaptor signatures correlated with poor outcome
as measured by recurrence-free and overall survival. Thus, IRS adaptor protein expression
is required for IGF ligand responses in breast cancer cells. IRS-specific gene signatures
represent accurate surrogates of IGF activity and could predict response to anti-IGF therapy
in breast cancer.
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Introduction
The insulin-like growth factor (IGF) pathway mediates cancer cell proliferation, survival, and
metastasis. These ligands interact with the type 1 IGF receptor (IGF-1R) and a number of
monoclonal antibodies and tyrosine kinase inhibitors have been developed and tested in clini-
cal trials. Although clinical benefit has been demonstrated in some cancers [1, 2], a lack of pre-
dictive biomarkers has hampered the ability to identify IGF-sensitive tumors. IGF-1R levels
have not consistently correlated with clinical benefit in trials evaluating IGF-1R inhibitors [3].
In contrast, circulating levels of IGF-I and IGF-II are associated with benefit from IGF-1R
inhibitors in the treatment of pancreatic cancer [4]. Since IGF-1R is dependent on ligand bind-
ing for activation [5], it is highly likely that biomarkers associated with receptor activation, and
not simply receptor expression, will be required to identify tumors sensitive to inhibition of
this pathway.
Insulin receptor substrate (IRS) proteins play a critical and differential role in mediating
receptor tyrosine kinase activity in breast cancer cells [6]. IGF-induced activation of IGF-1R
results in IRS-1 phosphorylation, cell proliferation, and activation of downstream signaling
molecules including PI3K and MAPK [7]. Conversely, IRS-2 stimulates adhesion and motility
predominantly through activation of PI3K [8]. More importantly, IRS proteins have a general
role in enhancing tumor cell growth, survival, and invasion [9]. The objective of this study was
to delineate isoform-specific (IRS-1 vs. IRS-2) global gene expression patterns.
Herein, we demonstrate that IRS adaptor proteins are required for IGF-ligand induced
biology and gene transcription. Target gene validation confirmed that both distinct and over-
lapping patterns of IRS-regulated gene expression are evident in response to IGF pathway
activation. The Late IRS-1 gene signature reported the highest significance in terms of func-
tional pathway analysis and gene set enrichment in molecular breast tumor subtypes. A high
correlation to the Late IRS-1 gene signature was a marker of poor prognosis independent of
nodal and/or hormone receptor status. IRS gene enrichment in luminal B breast tumors was
an independent predictor of both recurrence-free and overall survival. As a result, IRS adap-
tor signatures may distinguish patients that would benefit from anti-IGF targeted
therapeutics.
Materials and Methods
Cell Culture and Reagents
T47D-YA, and T47D-YA/IRS-1/2 cells were generated and described previously [10]. These
were provided as a gift from Dr. Kathryn. Horwitz (University of Colorado School of Medicine)
and were derived from the original parental T47D cell line [11]. Cells from animals with gene
deletion of IRS gene deletion [12, 13] and neuroblastoma cells with IRS overexpression [14]
were previously described. Gene deleted cells were obtained from the mouse models. Neuro-
blastoma SH-EP cells were a gift from Dr. Eva Feldman (University of Michigan Medical
School). Other cell lines were purchased from ATCC. Briefly, cell lines were maintained in
MEM (Invitrogen), 5% fetal bovine serum, penicillin/streptomycin, 1X non-essential amino
acids (Invitrogen), 6ng/L insulin (Humulin; Eli-Lily) and 50 μg/ml G418. 100 μg/ml hygromy-
cin B was added to IRS-1/2 cell culture media to maintain stable IRS-1/2 expression. Starvation
and IGF-I (5 nM) experiments were performed in serum-free media (SFM) (phenol red free
IMEM, 10 mMHEPES, pH 7.4, 1X trace elements, and 2 μg/ml transferrin) with or without
2 μg/ml fibronectin (FN). Transforming growth factor beta (TGFβ) neutralizing antibodies
were purchased from R&D Biosystems (Minneapolis, MN), AF-101-NA and AF-112-NA were
used to neutralize TGFβ1 and TGFβ2 respectively.
IRS Gene Expression Profiles
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Immunoblotting
Immunoblotting was performed as previously described [8]. Smad2 serine 465/467 phosphory-
lation was detected using antibody clone 138D4 (Cell Signaling).
Monolayer proliferation
Cells were plated in 24-well plates at a density of 10,000 cells per well, allowed to equilibrate
overnight and starved in SFMmedia for 24 hours prior to treatment with IGF-I. After 3 days of
treatment, growth was assessed via the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay as described previously (176). 60 μL of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide solution in SFM was added to each well. After incubation for
4 h at 37°C, wells were aspirated and formazan crystals were lysed with 500 μL of solubilization
solution (95% DMSO + 5% IMEM). Absorbance was measured with a plate reader at 570 nm
using a 650 nm differential filter to assess growth.
Scratch wound assay
Cells were plated in an 8-well scratch-wound plate at a density of 1x104 cells, allowed to equili-
brate overnight, starved in SFM overnight and a scratch induced manually employing a P10
pipette tip. The media was supplemented with or without IGF-I and monitored for 24 by light
microscopy and concurrent image acquisition. Values represent mean area cleared in IGF
treated groups vs. control SFM groups.
Boyden chamber assay
Cells were examined by Boyden chamber assay as previously described [8]. 0.4 ml SFM with or
without IGF (5nM) was placed in the bottom wells of the chamber. A polycarbonate polyvinyl-
pyrrolidone free filter (12μm pore size) was placed above this. Cells were detached in
PBS-EDTA and then were resuspended in SFM. 0.3 ml cell suspension (5x105 cells/ml) was
added to the top well chamber above the filter. To inhibit transforming growth factor beta
(TGFβ) species, antibodies were incubated at neutralizing dose concentrations (0.6μg/ml anti-
TGFβ1; 0.3μg/ml anti-TGFβ2) with the cells 30 minutes prior to placing in the chamber. The
chamber was then incubated for 6 hours at 37°C. At the end of the incubation, cells remaining
on the topside of the filter were scraped off with cotton swabs. The filter was then removed
from the chamber and the cells that had migrated to the underside of the filter were fixed and
stained in HEMA3. The filter was mounted on a glass microscope slide and cells were counted
in 10 different areas with the aid of a light microscope.
Microarray RNA isolation and analysis
Cells were plated at a density of 3x106 in 150 mm dishes, allowed to equilibrate overnight, and
the media replaced by SFM alone for 24 h prior to stimulation. At time = 0 cells were treated
with SFM+FN alone or with IGF-I. Total RNA was collected using RNeasy mini kit (Qiagen)
or PerfectPure RNA tissue kit (5Prime) at 4 h and 24 h. RNA quantity was determined by
260:280 assay and quality using the Agilent Bioanalyzer 2100 to ensure banding conservation.
Isolated RNA samples were then submitted to the Biomedical Genomics Center—Microarray
Facility University of Minnesota for biotin labeling, synthesis and hybridization to the Affyme-
trix U1330 Plus 2.0 arrays. Signatures are available through the GEO database (GSE78916).
IRS Gene Expression Profiles
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qPCR
Cells were plated at a density of 1x106 in 100mm diameter dishes, allowed to equilibrate and
incubated overnight in SFM. Cellular RNA was isolated using the 5 Prime PerfectPure RNA tis-
sue kit according to the manufacturer (Fisher Scientific). For quality control and to determine
nucleic acid concentration, a 260/280 assay was performed on a spectrophotometer. Forward
and reverse primers were designed to target the following transcripts: CCND1, GBP1, TGFβ2,
TNFSRF12A,MYBL2, SLC7A11, ADM, CDKN2B and RPLP0. A total of 2ug of RNA was
reverse transcribed using the Quantitect Reverse Transcriptase Kit and qPCR was performed
using the Quantifast SYBR Green Kit according to the manufacturer’s recommended protocol
(Qiagen) on an Eppendorf Mastercycler Realplex4 machine. The relative concentration of
mRNA was calculated using Ct values that were derived from a standard curve and normalized
to RPLP0 as an internal control.
Statistical analysis
All arrays were normalized using GC-RMA process embedded in GeneData refiner and further
normalized to corresponding untreated states to isolate IGF response independently of basal
differences between each of the cell lines. Student’s t tests were performed between groups
using GeneData expressionist with P-values< 0.05 (Bonferroni Correction in select cases) and
a minimum average fold change of 1.5 was employed. Hierarchical clustering was carried out
on log2-transformed data generated using Gene Cluster 3.0. Data was visualized and images
generated using Java TreeView. Molecular subtype classification and Kaplan-Meier analysis
was performed as previously described (15, 16). IRS expression profiles are submitted in the
Gene Expression Omnibus.
Results
IRS adaptor protein isoforms define tumor cell biology and regulate
specific global gene expression profiles
The T47D-YA breast cancer variant cell line does not express IRS adaptor proteins or respond
to IGF ligands, yet they retain functional IGF-1R [11]. These cells were employed as an isogenic
model to determine the role of IRS isoforms on gene expression in breast cancer. Proliferation
and motility was assessed in response to IGF-I ligand in IRS-null T47D-YA cells [10] and cells
expressing either human IRS-1 or IRS-2 (Fig 1A & 1B). IGF-I stimulated proliferation in IRS-1
cells and motility in IRS-2 cells. Cells lacking IRS proteins did not respond to IGF-I highlight-
ing the importance of adaptor protein expression in regulating IGF-mediated biology (data not
shown and Fig 1C). Multiple IRS-1 and IRS-2 clones [IRS-1 (#10 and #20) and IRS-2 (#1 and
#6)] were included in these and all subsequent analyses as a means to circumvent both clonal
and temporal bias and more accurately depict the role of IRS adaptor proteins in breast tumor
biology.
To assess the contribution of IRS adaptor proteins in the regulation of gene expression, IRS-
null, IRS-1, and IRS-2 cells were stimulated with IGF-I for a period of 4 or 24 hours and cDNA
microarray analysis performed (GSE78916). Unsupervised hierarchical clustering revealed sig-
nificant gene induction by both IRS-1 and IRS-2 at both early and late time points (Fig 1C). To
confirm the results from the engineered cell line, we used other IRS-expressing cells (MCF-7)
and a previously published IGF-I induced expression profile [17] (S1 Fig). While the number
of early genes induced by IGF-I was similar across IRS-expressing lines, IRS-1 cells had a
>3-fold increase in significantly expressed genes at the 24 hour time point. Importantly, IGF-I
did not induce gene transcription in IRS-null cells.
IRS Gene Expression Profiles
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IRS isoforms mediate distinct gene expression profiles, functional
pathways, and breast cancer subtype association
To assess the value of IRS adaptor proteins in breast cancer outcome, distinct IRS isoform gene
signatures were derived from the global gene expression patterns observed in response to IGF
stimulation (Fig 2A). Since marked differences were found at early and late time points, the fol-
lowing four gene signatures were derived: Early IRS-1, Late IRS-1, Early IRS-2 and Late IRS-2.
A subset of genes was validated by quantitative PCR (qPCR) as shown in Fig 2B. IGF-regulated
probes meeting both fold (1.5) and p-value (0.05) cutoff values that were commonly regulated
between each isoform clone were used to generate each isoform gene signature. As a confirma-
tory measure, IRS-null cells reported no change in response to IGF-I (Fig 1C and data not
Fig 1. IRS adaptor protein isoforms define tumor cell biology and regulate global gene expression profiles. (A) Monolayer growth and motility of
T47D-YA (YA), T47D-YA-IRS-1 (#10 and #20) and T47D-YA-IRS-2 (#1 and #6) were measured by MTT assay and (B) scratch-wound healing assay in
response to IGF-I treatment. The graphs are presented as fold-change response vs. non-treated control and error bars represent standard deviation. (C) IGF-
induced gene expression is IRS-dependent. cDNAmicroarray analysis was performed on IRS-null YA, IRS-1, and IRS-2 clones. The graph represents IGF-
regulated probes in comparison to untreated samples that met both fold (1.5) and p-value (0.05) cutoff values. Hierarchical clustering was carried out on
log2-transformed using Gene Cluster 3.0 and visualized in Java TreeView.
doi:10.1371/journal.pone.0150564.g001
IRS Gene Expression Profiles
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Fig 2. IRS isoformsmediate distinct gene expression profiles, functional pathways, and breast cancer
subtype association. (A) Venn diagrams depicting four distinct IRS isoform gene signatures were derived
from overlapping and differential global gene expression patterns in response to IGF-I. (B) Target gene
validation confirms both distinct and overlapping patterns of IRS-regulated gene expression. Gene
IRS Gene Expression Profiles
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shown). Functional pathway analysis revealed significant differences that were both isoform-
and time-dependent (Table 1).
Using median expression values, IRS gene signatures were significantly enriched according
to molecular breast tumor subtype (basal-like, claudin-low, HER2-enriched, luminal A, lumi-
nal B, and normal-like) in the UNC337 (GSE18229) cohort (Fig 2C) [15, 16]. The Late IRS-1
gene signature showed the most significant enrichment in basal-like, HER2-enriched, and
luminal B breast cancers (P = 1.03E-49). These data were confirmed in the NKI-295 cohort
([18], data not shown).
IRS-regulated genes affect tumor cell biology
To examine the biological significance of IRS-induced gene expression, we evaluated the induc-
tion of TGFβmRNA by both IRS-1 and IRS-2 in breast cancer cells. TGFβ2 was selected for
evaluation as both IRS-1 and -2 T47D transfected cells regulated this gene but not the related
growth factor TGFβ1 (Fig 3A). Furthermore, the regulation of TGFβ2 by IGF-I was confirmed
in other breast cancer cell lines (MCF-7L, MCF-7ATCC, MDA-231 and F11) as measured by
qPCR, but not in the normal MCF10A cells (Fig 3B).
In addition, we evaluated alternate IRS models to further confirm IRS-dependent TGFβ2
expression (Fig 3C). Analysis of mammary tumor RNA obtained from an IRS-gene deleted
mouse model [19] (left axis) and an IRS-overexpression SH-EP neuroblastoma model [14]
(right axis). While modulation of both IRS isoforms resulted in decreased (IRS knockout) or
increased (IRS overexpression) TGFβ2 expression, IRS-2 appeared more strongly associated
with TGFβ2 expression.
To test for functionality of IGF-induced TGFβ in MCF7 cells, we examined activation of the
TGFβ signaling pathway. IGF transiently induced the phosphorylation of SMAD2, an effector
of TGFβ signaling (Fig 3D). Since TGFβ signaling could be initiated by IGF, we evaluated
whether neutralization of TGFβ could suppress IGF-induced motility. Cell motility was exam-
ined using a modified-Boyden chamber in the presence of neutralizing TGFβ1 or TGFβ2 anti-
bodies (Fig 3E). IGF-induced motility was completely neutralized by TGFβ2 inhibition, while
TGFβ1 inhibition had no effect. Therefore, IGF-induced TGFβ2 expression drives cell motility
in MCF7 breast cancer cells. In this case, TGFβ2 induction enhanced cell motility. Moreover,
we have also shown that induction of other genes regulated by IRS function are relevant to cell
growth and survival [20].
expression was normalized to RPLP0 and is presented as fold-change of treatment (black bars) vs. serum-
free (white bars) conditions. Error bars represent standard deviation and all results are representative of at
least three independent replicates. (C) IRS gene signature enrichment in breast tumor subtypes in the
UNC337 cohort. Median expression values are represented here in graphical format with p-values included
for each of the IRS gene signatures.
doi:10.1371/journal.pone.0150564.g002
Table 1. Gene set enrichment analysis for each IRS gene signature was performed using DAVID (Database of Annotation, Visualization and Inte-
grated Discovery, v6.7). P-value indicates modified Fisher’s exact Probability Value and a high E-Scores (Enrichment Scores) indicates significant gene
enrichment in the annotation cluster.
Signature Pathway (KEGG) P-value Function (Annotation Cluster) P-value E-Score
Early IRS-1 P53 signaling pathway 1.9E-02 Transcription 4.2E-02 1.65
Late IRF-1 Cell cycle 1.8E-03 Mitosis 2.1E-16 10.67
Early IRS-2 Focal adhesion 1.2E-02 Regulation of protein kinase activity 2.8E-04 3.25
Late IRS-2 P53 signaling pathway 1.1E-02 Microtubule cytoskeleton 3.1E-05 2.89
doi:10.1371/journal.pone.0150564.t001
IRS Gene Expression Profiles
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Fig 3. IRS proteins regulate TGFβ2 mRNA expression and breast cancer cell motility. (A) Expression of TGFβ1 and TGFβ2 by qPCR in T47D-YA-IRS-
1 (#10 and #20) and T47D-YA-IRS-2 (#1 and #6). (B) IGF-induced TGFβ2 expression in MCF10A, MCF-7L, MCF-7 ATCC, MDA-231 and F11 cells. For A &
B, all cells were exposed to 5nm IGF-I for 4 hours prior to harvesting mRNA. Gene expression was normalized to RPLP0 and is presented as fold-change of
treatment (black bars) vs. serum-free (white bars) conditions. (C) TGFβ2 expression was assessed by qPCR in an IRS-gene deletion mouse models (left)
and IRS-overexpressing SH-EP neuroblastoma cells (right). (D) IRS-1, IRS-2 and TGFβ2 expression in a panel of patient breast tumors. Arrows indicate
invasive breast carcinoma. Yellow bars signify high gene expression, blue bars signify low gene expression. E) pSMAD2 was examined by immunoblot at the
indicated time points in MCF-7 cells. (F) Cell motility was examined by modified Boyden chamber assay. MCF-7 cells were incubated in the presence of
neutralizing antibodies to either TGFβ1 or TGFβ2 and IGF-induced motility assessed. Error bars represent standard deviation and all results are
representative of at least three independent replicates.
doi:10.1371/journal.pone.0150564.g003
IRS Gene Expression Profiles
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Late IRS-1 gene expression is associated with poor relapse-free and
overall survival
To evaluate the clinical impact of the IRS signatures, we analyzed their expression in the
UNC337 and NK1295 cohorts. The Late IRS-1 signature was most significantly over-repre-
sented across the subtypes and as a result, its prognostic value was determined in breast cancer
tumors. To this end, tumors were divided into three groups by Late IRS-1 expression values:
“Strong IRS-1 Corr.” (upper 20% or most positive correlation values), “Inverse IRS-1 Corr.”
(lower 20% or most negative correlation values) or “Weak IRS-1 Corr.” (remaining 60% or
mid-range correlation values). In both the UNC337 and NKI295 cohorts, poor outcome was
significantly associated with increased Late IRS-1 gene expression for both recurrence-free sur-
vival (RFS) (P =< 0.0001) and overall survival (OS) (P =< 0.0001) (Fig 4A and 4B). Stratifica-
tion of tumors by nodal and/or ERα status did not affect this association (S2 Fig).
Separating tumors by molecular subtype revealed that Luminal B tumors with increased
Late IRS-1 gene expression had poor RFS and OS (S1 Table). While increased Late IRS-1 gene
expression in Luminal A tumors was associated with poor RFS, no significant correlations were
revealed in the remaining molecular subtypes (data not shown). Univariate analysis yielded
highly significant differences among all tumors in RFS (P = 0.0016) and OS (P<0.0015) (Fig
4A & 4B). In multivariate analysis, Late IRS-1 was the most significant prognostic risk factor
for both RFS (HR = 2.463, 95% CI = 1.185–4.900, P = 0.0167) and OS (HR = 2.831, 95%
CI = 1.147–6.637, P = 0.025) (Table 2). In addition, 5-year estimates of recurrence and survival
are presented (S1 Table).
At 5 years, a strong IRS-1 Late correlation resulted in significantly shorter recurrence
(P = 0.0111) and survival (P = 0.0085) rates than patients with a weak IRS-1 Late correlation.
Discussion
Identifying IGF-dependent breast cancer tumors remains a challenge. While levels of total and
IGF-1R have been identified as poor prognostic factors in breast cancer [21], levels of IGF-1R
expression have not been shown to predict benefit from anti-IGF therapeutics (reviewed in
[22]). Expression levels do not identify activated signaling pathways and it seems likely that
development of biomarkers that indicate IGF-1R mediated signaling will be more useful. For
example, levels of the IGF ligands predict benefit from the IGF-1R monoclonal antibody
Fig 4. Late IRS-1 gene expression is a marker of poor prognosis. Univariate Kaplan-Meier analysis of A) RFS and B) OS was assessed in the combined
UNC3337 and NKI295 cohorts (n = 534). Tumors were subdivided and classified as one of the following: Strong IRS-1 Corr. (top 20% of all tumors), Inverse
IRS-1 Corr. (bottom 20% of all tumors), andWeak IRS-1 Corr. (all remaining tumors). Corresponding p-values are depicted.
doi:10.1371/journal.pone.0150564.g004
IRS Gene Expression Profiles
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ganitumab in pancreas cancer [4] supporting the idea that receptor activation is an important
predictive biomarker for anti-IGF-1R drugs.
Using an in vitromodel system, we show that IRS adaptor proteins are necessary for IGF-
1R mediated biology. This observation was supported by evaluating transcriptional changes
after IGF-I exposure. Previous studies have used a similar approach using cell lines to develop
an “IGF activated” signature [17]. Our work adds to this observation by delineating the neces-
sity of IRS proteins in regulating IGF-1R mediated transcription. Strikingly, transcript regula-
tion was completely absent in IGF-1R-positive/IRS-null cells. In addition, distinct gene
expression profiles were dependent on both IRS species and time. Taken together, these data
demonstrate that gene expression profiles are dependent on activation of specific adaptor pro-
teins downstream of IGF-1R and not due to receptor expression alone.
In addition to providing predictive biomarkers for anti-IGF-1R therapies, identification of
key genes regulated by activation of this pathway may be useful. One of the genes we identified
as regulated by IRS-1 (SLC7A11 or xCT) has a functional role in mediating response to reactive
oxygen species [20]. While we discovered this gene through our study of IRS-stimulated gene
expression, it is notable that xCT also has a role in triple negative breast cancers [23].
We studied IGF signaling in this model system, it is also clear that the IRS adaptor proteins
regulate insulin receptor signaling [24]. As we have recently shown, endocrine resistant cells
may rely more heavily on insulin receptor than IGF receptor [25]. The failure of ganitumab, an
IGF-1R monoclonal antibody, in the treatment of metastatic endocrine resistant breast cancer
might be due to the continued signaling via insulin receptor stimulation of IRS adaptor pro-
teins [26]. We are currently developing methodologies to confirm whether both insulin and
IGF stimulation of their receptors result in the same, or different, profiles.
We conclude that IRS adaptor proteins represent potential predictive clinical biomarkers of
breast cancer outcome and should be considered in conjunction with receptor expression. Fur-
thermore, both receptor and adaptor protein targeting might result in enhanced suppression of
growth factor signaling and inhibition of tumor growth.
Supporting Information
S1 Fig. Patterns of global IGF-induced gene regulation are highly conserved. Comparative
analysis of T47D-YA/IRS-1 and MCF-7 gene arrays was performed and IGF-induced gene
overlap determined. Arrays represent both temporal and directional overlap. Results were
Table 2. Multivariate Cox regression analysis of RFS & OS in Luminal B breast cancer tumors.
RFS OS
HR (95% CI) P HR (95% CI) P
Age 0.642 (0.378–0.987) 0.0426 0.526 (0.248–1.009) 0.0537
Size
2 1.464 (0.759–2.874) 0.2559 1.635 (0.690–3.979) 0.2640
3 2.736 (0.607–8.928) 0.1687 8.229 (1.096–41.60) 0.0419
Grade
2 0.588 (0.217–1.863) 0.3412 1.30 (0.2.55–6.906) 0.9699
3 0.871 (0.323–2.778) 0.7994 1.495 (03.60–10.27) 0.6092
Node
1 0.985 (0.503–1.938) 0.9658 1.055 (0434–2.563) 0.9045
2 0.774 (0.294–1.828) 0.5713 1.069 (0.326–3.047) 0.9054
IRS-1 Corr. 2.463 (1.185–4.900) 0.0167 2.831 (1.147–6.637) 0.0250
doi:10.1371/journal.pone.0150564.t002
IRS Gene Expression Profiles
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confirmed by Fisher’s exact test.
(TIFF)
S2 Fig. Late IRS-1 expression assessed by nodal and ERα status. Kaplan-Meier analysis strat-
ified (n = 534) according to nodal and/or ERα status. Strong Late IRS-1 gene expression is asso-
ciated with poor prognosis in all groups
(TIFF)
S1 Table. Odds ratios of Luminal B breast cancer tumors depicting RFS & OS at 5 years in
the Strong Late IRS-1 correlation vs. Weak Late IRS-1 correlation groups.
(DOCX)
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